Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide. 1 It is a
heterogeneous disease, comprising distinct biologic entities with different prognosis and …

Simple Summary Breast cancer can express, at varied levels, a protein named HER2,
commonly responsible for making it grow and send distant metastases. In the past, patients …

About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be
targeted by new antibody-drug conjugates. The main aim of this study is to describe the …

PURPOSE Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk
for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the …

Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-
positive expression. We recently described a high instability of HER2-low-positive …

Breast cancer is a heterogeneous disease, and stratification of tumors is paramount to
achieve better clinical outcomes. While it is common to stratify and treat breast tumors as a …

Although breast cancer stem cells (BCSCs) display plasticity transitioning between
quiescent mesenchymal-like (M) and proliferative epithelial-like (E) states, how this plasticity …

Previous studies have suggested that breast cancer stem cells (BCSCs) mediate metastasis,
are resistant to radiation and chemotherapy, and contribute to relapse. Although several …

Circulating tumour cells in women with advanced oestrogen-receptor (ER)-positive/human
epidermal growth factor receptor 2 (HER2)-negative breast cancer acquire a HER2-positive …

As the culprit behind most cancer-related deaths, metastasis is the ultimate challenge in our
effort to fight cancer as a life-threatening disease. The explosive growth of metastasis …